Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue
The Company Stabilized Its US Oncology Biosimilar Revenue After Past Drops
Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.
